Durham – September 16, 2026 -- Seismic Pharmaceuticals has enrolled the first patient in its global Phase 3 trial testing istaroxime for heart-failure-related cardiogenic shock, a condition with no FDA-approved pharmacologic therapy. The study, RESCUE HF-CS, targets approximately 600 patients recruited at clinical sites across the United States, Europe, China and South America.

Durham – September 15, 2026 -- Seismic Pharmaceuticals has enrolled the first patient in RESCUE HF-CS, a global Phase 3 trial testing istaroxime as a potential first-ever approved drug for heart-failure-related cardiogenic shock, a condition with no FDA-approved treatment.

Trial to enroll 600 patients across four continents

The study will recruit approximately 600 patients at clinical sites in the United States, Europe, China and South America. It builds on four completed Phase 2 trials that enrolled more than 350 patients.

Durham – September 15, 2026 -- Seismic Pharmaceuticals has commenced a global Phase 3 trial of Istaroxime, aiming to deliver the first-ever approved drug for cardiogenic shock, a condition with no currently FDA-approved treatments.

Trial to enroll 600 patients across three continents

The study, named Rescue HF CS, will recruit approximately 600 patients at clinical sites in the United States, Europe and South America. It builds on four completed Phase 2 trials in which more than 340 patients received Istaroxime.